Results

Total Results: 1,653 records

Showing results for "described".

  1. effectivehealthcare.ahrq.gov/sites/default/files/related_files/treatment-resistant-depression_disposition-comments.pdf
    September 01, 2011 - We believe this rational is clearly described in the Introduction at the end of the “Patient Populations … BA 25) has substantial efficacy in experimental studies, yet this is not described. … The characteristics of the studies are clearly described and key messages are stated explicitly and … The limitations of the review/studies are described adequately. … described and not a part of eligibility criteria for study).
  2. effectivehealthcare.ahrq.gov/sites/default/files/related_files/peripheral-artery-disease-treatment_disposition-comments.pdf
    May 29, 2013 - The search, inclusion and exclusion criteria are well described. … Peer Reviewer 3 Methods Very sound methods that are clearly described. Thank you. … Outcome measures are appropriate and described adequately. … TEP Member 4 Results Characteristics of the studies are clearly described in the report and (in a more … The numerous and serious limitations of the studies/review are clearly described (best in Executive
  3. Dia 1 (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/ijzerman_ahrq-webinar-mcda.pdf
    January 01, 2011 - Dia 1 1 Integrating stakeholder preferences in comparative effectiveness research using multi-criteria decision analysis (MCDA) and Conjoint Analysis (CA) Maarten J. IJzerman, PhD Professor and chair, department Health Technology & Services Research m.j.ijzerman@utwente.nl Multiple endpoints in …
  4. effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-208-bipolar-adults-disposition-comments.pdf
    August 07, 2018 - There are some issues with the search strategy as described in the general comments attachment. … In several locations in the document, study findings are described as "mixed" but no other details or … Currently, the study is described in one part of the document but not others. … Results – Overall Peer Reviewer #5 The included studies are well-described and the informative … “Handling of data from missing persons not described” Refer to figure 1.
  5. effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-195-disposition-comments-uterine-fibroids.pdf
    December 14, 2017 - We revised SOE here and later in the report as described below in the reply to comments in the more … Ullipristal is described as follows: Ulipristal acetate (Ella®, Esmya®) is a selective progesterone … We reported potential harms as described in the included studies (now including Donnez). … We reported potential harms as described in the included studies (now including Donnez). … The characteristics of the studies are clearly described, with key messages clearly communicated.
  6. effectivehealthcare.ahrq.gov/sites/default/files/palliative-care-tools-disposition.pdf
    May 04, 2017 - of relevant issues and gaps” 24 Peer Reviewer #3 Methods The Methods section overall clearly described … that it was important to solicit their opinions on all aspects of the project given their role as described … clinical assessment, QI, Research, Accountability) The intended use of the tools was not generally described … We have clarified for pain and dyspnea: “As described in the National Consensus Guidelines for Quality … Quality of life tools do include physical functioning, as described in the definition in the beginning
  7. effectivehealthcare.ahrq.gov/sites/default/files/related_files/palliative-care-tools-disposition.pdf
    May 04, 2017 - of relevant issues and gaps” 24 Peer Reviewer #3 Methods The Methods section overall clearly described … that it was important to solicit their opinions on all aspects of the project given their role as described … clinical assessment, QI, Research, Accountability) The intended use of the tools was not generally described … We have clarified for pain and dyspnea: “As described in the National Consensus Guidelines for Quality … Quality of life tools do include physical functioning, as described in the definition in the beginning
  8. effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-201-indoor-allergen-asthma-disposition-comments.pdf
    February 15, 2018 - Thus, we encourage the Agency to finalize this Draft Report with the suggested modifications described … All of these approaches are now described more fully in the Results, and and the limitations of our … As described in the Methods, we used AHRQ EPC methods to guide our assessment of the body of evidence … Study characteristics are well described. Thank you. … All of these approaches are not described more fully in the Results, and the limitations of our analysis
  9. effectivehealthcare.ahrq.gov/sites/default/files/related_files/high-risk-drugs-protocol.pdf
    July 27, 2023 - • Unspecified study designs or comparison group not described.
  10. effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-211-rheumatoid-arthritis-disposition-comments.pdf
    December 20, 2018 - Peer Reviewer #1 Evidence Summary ES-3, lines 26-32 Clarify all DAS28 scores described are baseline … The ranges of DAS28 scores described for each drug category capture both mean and median values of our … If one changes and others do not, this is described in the detailed results. … Peer Reviewer #3 Introduction Nulliparity was described as a risk factor for RA (page 1, line 20) … Peer Reviewer #3 Methods Throughout the document, studies involving MTX are described and results
  11. effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-221-copd-comments_0.pdf
    October 11, 2019 - page 22+): The content is not linked to KQ nor SOE descriptions; suggest replacing with the table described
  12. McCullough (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/mccullough.pdf
    January 01, 2011 - McCullough Slide  1: An Ethical Framework for Supporting  Shared Decision Making  When Clinical Evidence is Low Laurence B. McCullough, Ph.D. Dalton Tomlin Chair in Medical Ethics and Health Policy Associate Director for Education Center for Medical Ethics and …
  13. effectivehealthcare.ahrq.gov/sites/default/files/pdf/multiple-sclerosis_research-protocol.pdf
    December 17, 2013 - review based on the PICOTS framework outlined in Section II and the study-specific inclusion criteria described … www.effectivehealthcare.ahrq.gov Published online: December 17, 2013 9 results to planned analysis described … in trial registries and/or the methodology section of the publication as described in a recent AHRQ
  14. effectivehealthcare.ahrq.gov/sites/default/files/pdf/weight-loss-surgery_research-protocol.pdf
    December 14, 2010 - Population(s): Demographic subsets of the populations described in KQ1. … for this Comparative Effectiveness Review, with the five key questions depicted within the context described … Studies will be included that address the populations, interventions, comparators, and outcomes described
  15. effectivehealthcare.ahrq.gov/sites/default/files/pdf/labor-nitrous-oxide_research-protocol.pdf
    August 24, 2011 - used nitrous oxide (likely an overestimate considering how few U.S. facilities offer this method as described … Bishop has briefly described the UCSF practices in ―Administration of Nitrous Oxide in Labor: Expanding … (e.g., Nitronox) is the most common method of nitrous oxide administration for labor pain relief described
  16. effectivehealthcare.ahrq.gov/sites/default/files/pdf/diabetes-glucose-control_research.pdf
    July 01, 2010 - We categorized patients by medication use and by their first fill-date of exenatide, and described the … For descriptive purposes, we reported the means and percentages of the variables described above. … After creating the cohort, as described in the methods, we studied the 3,225 patients who filled exenatide
  17. effectivehealthcare.ahrq.gov/sites/default/files/pdf/pediatric-ehr_research-protocol.pdf
    January 01, 2014 - policy makers, and professional organizations such as the American Academy of Pediatrics (AAP) have described … meet pediatric functionality and workflow demands could be potentially dangerous.10 Some studies have described … Healthcare Research and Quality (AHRQ),41 Health Level 7 (HL7) International,42 and the AAP3 have described
  18. effectivehealthcare.ahrq.gov/sites/default/files/study-design-considerations-chapter-2.pptx
    January 01, 2013 - Commonly used comparative effectiveness research study designs are described, and key design features … exposure classification (heart transplant or not) should not be attributed to the heart transplant and is described … Approaches to empirical identification of confounders should be described if planned.
  19. effectivehealthcare.ahrq.gov/sites/default/files/related_files/quality-gap-palliative-hospice_executive.pdf
    October 01, 2012 - We included 90 studies described in 96 articles in the review (Figure B). … We described the information abstracted in a systematic manner but did not conduct any meta-analyses … Coordination of Care, and Transitions Key Question 1a: Evidence About Target We found 23 studies described
  20. effectivehealthcare.ahrq.gov/sites/default/files/module-iii-points-of-engagement-in-the-ehc-program.pdf
    May 29, 2025 - Module III: Points of Engagement in the EHC Program …

Search the AHRQ Archive

Information and reports more than 5 years old may be found in the AHRQ Archive site.

Search Archive

Search Within A Specific AHRQ Site

You selected to view results for the following site: